Rapid Point-of-Care Test for Determination of C-Peptide Levels. (July 2022)

• Record Type: Journal Article
• Authors: Rao, Paturi V.; Bean, Eric; Nair-Schaef, Dhanalakshmi; Chen, Siting; Kazmierczak, Steven C.; Roberts, Charles T.; Nagalla, Srinivasa R.
• Is Part Of: Journal of diabetes science and technology. Volume 16:Number 4(2022)
• Page Start: 976
• Page End: 981
• Publication Date: 2022-07
• Subjects: C-peptide -- LADA -- MODY -- point-of-care -- diabetes; Diabetes -- Periodicals; Medical technology -- Periodicals; Diabetes Mellitus -- Periodicals; 616.462005
• DOI: 10.1177/1932296821995557
• Languages: English
• ISSNs: 1932-2968

Abstract

C-peptide is co-secreted with insulin and is not subject to hepatic clearance and thus reflects functional β-cell mass. Assessment of C-peptide levels can identify individuals at risk for or with type 1 diabetes with residual β-cell function in whom β cell-sparing interventions can be evaluated, and can aid in distinguishing type 2 diabetes from Latent Autoimmune Diabetes in Adults and late-onset type 1 diabetes. To facilitate C-peptide testing, we describe a quantitative point-of-care C-peptide test. C-peptide levels as low as 0.2 ng/ml were measurable in a fingerstick sample, and the test was accurate over a range of 0.17 to 12.0 ng/ml. This test exhibited a correlation of r = 0.98 with a high-sensitivity commercial ELISA assay and a correlation of r = 0.90 between matched serum and fingerstick samples.